Inflammation can occur months after intravitreal therapy is started, and it can lead to severe vision loss. Follow these tips to screen for and manage treatment-triggered uveitis.
Stabilizing the volume of exudative fluid, including subretinal fluid, may help maximize anti-VEGF treatment outcomes for patients with nAMD.
Although anti-VEGF therapy is the current gold-standard treatment for retinal vein occlusion, not all patients respond to it. A study has found that volume of intraretinal fluid, among other factors detectable with optical coherence tomography, may help predict treatment response.
Standard treatment for nAMD involves repeated anti-VEGF injections. A recent study has found that an investigational therapy, administered through a bioerodible insert in the vitreous cavity, reduced treatment burden by 74% in one year.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Faricimab, a new drug for nAMD, offers patients similar benefits at 16-week intervals as aflibercept at eight-week intervals, a study shows.
Patients with diabetic eye disease or vein occlusion lost more vision than patients with age-related macular degeneration when they missed an intravitreal injection during the COVID-19 shutdown.
Study finds that patients with more severe diabetic retinopathy have faster resolution of diabetic macular edema after anti-VEGF treatment than patients with less severe diabetic retinopathy.
Study associates leakage patterns and tortuosity in retinal blood vessels with anti-VEGF therapy interval tolerance in patients with diabetic eye disease or retinal vein occlusion.
A lapse in anti-VEGF therapy can cause an irreversible decrease in visual acuity in neovascular age-related macular degeneration.
Study shows that baseline presence of and changes in DRIL burden during the course of disease in RVO is a useful prognostic indicator for VA and can help guide treatment with anti-VEGF therapy.